Screening of abdominal obesity and diabetes mellitus in women with oncological diseases

Main Article Content

N.O. Pertseva
M.K. Rokutova
V.V. Melnik


Background. The purpose of the study was to assess the presence of excess body weight, abdominal obesity (AO), and type 2 diabetes mellitus (DM) in oncological diseases in women of young and middle age. Materials and methods. 32 outpatient women aged 31 to 59 years with a verified oncological disease were examined. Standard clinical methods of investigation, statistical processing of results by nonparametric statistics were used. Results. Cervical cancer was verified in 24 (75.0 %) persons, breast adenocarcinoma — in 5 (15.6 %), rectal cancer — in 3 (9.4 %) patients. Elevated body mass index was detected in 24 (75.0 %) women: excess body weight — in 11 (34.4%), AO stage I — in 8 (25.0%), stage II — in 5 persons (15.6 %). Overweight or AO were detected in 30 (93.8 %) patients according to waist-to-height ratio. Type 2 DM was detected only in 2 patients (6.3 %). A heredity in oncopathology was recorded in half of women, of them for AO — in 8 (25.0 %), for type 2 DM — in 5 (15.6 %) patients. A direct correlation was established between heredity in oncological disease and body weight (r = 0.62, p < 0.01), waist circumference (r = 0.61, p < 0.01), body mass index (r = 0.66, p < 0.01), waist-to-height ratio (r = 0.49, p <0.05), waist circumference/hip circumference ratio (r = 0.41, p < 0.01). Conclusions. Overweight and obesity are common among women with cancer, especially, with cervical cancer. Correlation between increased anthropometric indicators and a family history of oncological diseases among women was noted. For comprehensive diagnosis of overweight, in addition to the standard anthropometric indicators, the waist-to-height ratio should be used, as well as additional examinations to detect type 2 DM, insulin resistance, metabolic changes.

Article Details

How to Cite
Pertseva, N., M. Rokutova, and V. Melnik. “Screening of Abdominal Obesity and Diabetes Mellitus in Women With Oncological Diseases”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 8, Dec. 2017, pp. 586-90, doi:10.22141/2224-0721.13.8.2017.119275.
To practicing Endocrinologists


Alexandrova AY. Plasticity of tumor cell migration: Acquisition of new properties or return to the past? Biochemistry (Moscow). 2014;79(9):947-963. (in Russian).

Pankiv VI. Advantages of the combined therapy with metformin and glimepiride in patients with type 2 diabetes mellitus. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2017;13(2):118-122. doi: 10.22141/2224-0721.13.2.2017.100598. (in Ukrainian).

Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci (Landmark Ed). 2011 Jan 1;16:1634-50. PMID: 21196253.

Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014 Aug 30;384(9945):755-65. doi: 10.1016/S0140-6736(14)60892-8.

Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301-16. doi: 10.1146/

Boeing H. Obesity and cancer – the update 2013. Best Pract Res Clin Endocrinol Metab. 2013 Apr;27(2):219-27. doi: 10.1016/j.beem.2013.04.005.

National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. Bethesda (MD): National Heart, Lung, and Blood Institute; 1998 Sep.

Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol. 2006 Nov;169(5):1505-22. doi: 10.2353/ajpath.2006.051090.

De Pergola G, Silvestris F. Obesity as a Major Risk Factor for Cancer. J Obes. 2013;2013:291546. doi: 10.1155/2013/291546.

Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to antineoplastic effects of metformin in vivo. Oncogene. 2011 Mar 10;30(10):1174-82. doi: 10.1038/onc.2010.483.

Gallagher EJ, LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology. 2011 Jul;152(7):2546-51. doi: 10.1210/en.2011-0231.

Dutta D, Ghosh S, Pandit K, Mukhopadhyay P, Chowdhury S. Leptin and cancer: pathogenesis and modulation. Indian J Endocrinol Metab. 2012 Dec;16(Suppl 3):S596-600. doi: 10.4103/2230-8210.105577.

Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem. 2009 May;115(2):86-96. doi: 10.1080/13813450902878054.

Most read articles by the same author(s)